EMA Recommends Granting a Marketing Authorisation for Lurbinectedin By Ogkologos - April 30, 2026 5 0 Facebook Twitter Google+ Pinterest WhatsApp It is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian Patient Guide in Bladder Cancer Now Available Also in French MOST POPULAR Cancer in Lymph Nodes May Help Tumors Spread by Enlisting Immune... May 27, 2022 Molecular Analysis for Precision Oncology Congress 2022, 14-16 October 2022, Amsterdam,... September 29, 2022 6 things you need to know about cervical screening October 25, 2021 Dad Is Making Baby Giggle, But When He Makes A Sheep... May 21, 2019 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΤΩΝ ΟΣΤΩΝ One Family’s Mission to Stop Hair Loss from Chemotherapy: Your Stories... At 27, She Was Told She Was Too Young For Breast... Pink Speed Bump Reminds Drivers to Schedule Their Yearly Mammograms
